skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Risk of “silent stroke” in patients older than 60 years: risk assessment and clinical perspectives

Review

(3180) Views  (1060) Full article downloads

Authors: Jae-Sung Lim, Hyung-Min Kwon

Published Date September 2010 Volume 2010:5 Pages 239 - 251
DOI: http://dx.doi.org/10.2147/CIA.S7382

Jae-Sung Lim1, Hyung-Min Kwon2

1Department of Neurology, Armed Forces Seoul Hospital, Seoul, Republic of Korea; 2Department of Neurology, Seoul National University Boramae Hospital, Seoul, Republic of Korea

Abstract: With the increasing size of the elderly population and evolving imaging technology, silent brain infarction (SBI) has garnered attention from both the public and the physicians. Over 20% of the elderly exhibit SBI, and the prevalence of SBI increases steadily with age, ie, 30%–40% in those older than 70 years. Well-known cardiovascular risk factors such as hypertension has been identified as a risk factor of SBI (odds ratio [OR] = 3.47) Besides this, blood pressure (BP) reactivity to mental stress, morning BP surges, and orthostatic BP changes have been demonstrated to contribute to the presence of SBI. Further, a metabolic syndrome not only as a whole syndrome (OR = 2.18) but also as individual components could have an influence on SBI. Increased C-reactive protein and interleukin-6, coronary artery disease, body mass index, and alcohol consumption have also been associated with SBI. The ORs and ­possible mechanisms have been discussed in this article. Overt stroke, dementia, depression, and aspiration pneumonia were all associated with SBI. (overt stroke: hazard ratio [HR] = 1.9, 95% confidence interval [CI]; 1.2–2.8; dementia: HR = 2.26, 95% CI: 1.09–4.70). We also looked into their close relationship with SBI in this review.

Keywords: silent brain infarction, elderly, risk factors, treatment








Readers of this article also read:

Alogliptin: a new addition to the class of DPP-4 inhibitors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Potential renovascular hypertension, space missions, and the role of magnesium
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Everolimus-eluting stents: update on current clinical studies
Metabolic pathway and distribution of superparamagnetic iron oxide nanoparticles: in vivo study